{"id":5481,"date":"2021-06-28T10:31:53","date_gmt":"2021-06-28T10:31:53","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=5481"},"modified":"2024-05-02T09:49:45","modified_gmt":"2024-05-02T07:49:45","slug":"granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/","title":{"rendered":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19"},"content":{"rendered":"
\n

Miki Koroku<\/a> 1<\/a><\/sup>, Teppei Omori<\/a> 1<\/a><\/sup>, Harutaka Kambayashi<\/a> 1<\/a><\/sup>, Shun Murasugi<\/a> 1<\/a><\/sup>, Tomoko Kuriyama<\/a> 1<\/a><\/sup>, Yuichi Ikarashi<\/a> 1<\/a><\/sup>, Maria Yonezawa<\/a> 1<\/a><\/sup>, Ken Arimura<\/a> 2<\/a><\/sup>, Kazunori Karasawa<\/a> 3<\/a><\/sup>, Norio Hanafusa<\/a> 4<\/a><\/sup>, Masatoshi Kawana<\/a> 5<\/a><\/sup>, Katsutoshi Tokushige<\/a> 1<\/a><\/sup> Intest Res. 2021 Mar 12. doi: 10.5217\/ir.2020.00148.<\/p>\n<\/div>\n\n

\n

In conclusion, our patient\u2019s case indicates that GMA for a patient with both active UC and COVID-19 is a safe treatment option for active UC that could lead other patients in this condition to remission.<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/<\/a><\/p>\n<\/div>\n\n

\n

https:\/\/irjournal.org\/upload\/pdf\/ir-2020-00148.pdf<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Miki Koroku 1, Teppei Omori 1, Harutaka Kambayashi 1, Shun Murasugi 1, Tomoko Kuriyama 1, Yuichi Ikarashi 1, Maria Yonezawa 1, Ken Arimura 2, Kazunori Karasawa 3, Norio Hanafusa 4, Masatoshi Kawana 5, Katsutoshi Tokushige 1 Intest Res. 2021 Mar 12. doi: 10.5217\/ir.2020.00148. In conclusion, our patient\u2019s case indicates that GMA for a patient with both active UC and COVID-19 is a safe treatment option for active UC that could lead other patients in this condition to remission. https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/ https:\/\/irjournal.org\/upload\/pdf\/ir-2020-00148.pdf<\/p>\n","protected":false},"template":"","scientific_tags":[147,325,321,424,306],"class_list":["post-5481","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission","scientific_tags-covid-19","scientific_tags-gastroenterology","scientific_tags-gma","scientific_tags-ulcerative-colitis"],"acf":[],"yoast_head":"\nGranulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Miki Koroku 1, Teppei Omori 1, Harutaka Kambayashi 1, Shun Murasugi 1, Tomoko Kuriyama 1, Yuichi Ikarashi 1, Maria Yonezawa 1, Ken Arimura 2, Kazunori Karasawa 3, Norio Hanafusa 4, Masatoshi Kawana 5, Katsutoshi Tokushige 1 Intest Res. 2021 Mar 12. doi: 10.5217\/ir.2020.00148. In conclusion, our patient\u2019s case indicates that GMA for a patient with both active UC and COVID-19 is a safe treatment option for active UC that could lead other patients in this condition to remission. https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/ https:\/\/irjournal.org\/upload\/pdf\/ir-2020-00148.pdf\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T07:49:45+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/\",\"name\":\"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2021-06-28T10:31:53+00:00\",\"dateModified\":\"2024-05-02T07:49:45+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/","og_locale":"es_ES","og_type":"article","og_title":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte","og_description":"Miki Koroku 1, Teppei Omori 1, Harutaka Kambayashi 1, Shun Murasugi 1, Tomoko Kuriyama 1, Yuichi Ikarashi 1, Maria Yonezawa 1, Ken Arimura 2, Kazunori Karasawa 3, Norio Hanafusa 4, Masatoshi Kawana 5, Katsutoshi Tokushige 1 Intest Res. 2021 Mar 12. doi: 10.5217\/ir.2020.00148. In conclusion, our patient\u2019s case indicates that GMA for a patient with both active UC and COVID-19 is a safe treatment option for active UC that could lead other patients in this condition to remission. https:\/\/pubmed.ncbi.nlm.nih.gov\/33902268\/ https:\/\/irjournal.org\/upload\/pdf\/ir-2020-00148.pdf","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T07:49:45+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/","name":"Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19 - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2021-06-28T10:31:53+00:00","dateModified":"2024-05-02T07:49:45+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-and-monocyte-apheresis-therapy-for-patients-with-active-ulcerative-colitis-associated-with-covid-19\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/5481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=5481"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=5481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}